Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients.
Faezeh MaghsoodDanesh HassaniVahid SalimiGholam Ali KardarJalal KhoshnoodiAbbas GhaderiSeyyed Reza RaeeskaramiAbdorrahman RostamianMonireh Sadat SeyyedsalehiRaoufeh Ahmadi FesharakiMahmood Jeddi-TehraniAmir-Hassan ZarnaniMohammad Mehdi AmiriMohammad-Reza ShokriPublished in: Viral immunology (2021)
The coronavirus infectious disease 2019 (COVID-19), which is initiated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has imposed critical challenges to global health. Understanding the kinetic of SARS-CoV-2-specific IgM and IgG responses in different subsets of COVID-19 patients is crucial to get insight into the humoral immune response elicited against the virus. We investigated IgM and IgG responses against SARS-CoV-2 nucleocapsid (N) and receptor-binding domain (RBD) of spike protein in two groups of recovered and deceased COVID-19 patients. The levels of IgM and IgG specific to N and RBD proteins were detected by ELISA. N- and RBD-specific IgM was higher in deceased patients in comparison with recovered patients, while there was no significant difference in N- and RBD-specific IgG between the two groups. A significant correlation was observed between IgG and IgM titers against RBD and N, in both groups of patients. These results argue against impaired antibody response in deceased COVID-19 patients.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- end stage renal disease
- immune response
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- coronavirus disease
- peritoneal dialysis
- global health
- dendritic cells
- kidney transplantation
- public health
- patient reported outcomes
- small molecule
- toll like receptor